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Abstract
Background & Aims: The gastrointestinal trefoil factor
family (TFF1, TFF2, TFF3) peptides are considered
to play an important role in maintaining the integrity
of the mucosa. The physiological role of TFF2 in the
protection of the GI tract was investigated in TFF2
deficiency. Methods: TFF2-/- mice were generated
and differential expression of various genes was
assessed by using a mouse expression microarray,
quantitative real time PCR, Northern blots or
immunohistochemistry. Results: On an mRNA level we
found 128 differentially expressed genes. We
observed modulation of a number of crucial genes
involved in innate and adaptive immunity in the TFF2-
/- mice. Expression of proteasomal subunits genes
(LMP2, LMP7 and PSMB5) involved in the MHC class
I presentation pathway were modulated indicating the
formation of immunoproteasomes improving antigen
presentation. Expression of one subunit of a
transporter (TAP1) responsible for importing
degraded antigens into ER was increased, similarly
to the BAG2 gene that modulates chaperone activity
in ER helping proper loading on MHC class I
molecules. Several mouse defensin (cryptdin) genes
coding important intestinal microbicidal proteins were
up-regulated as a consequence of TFF2 deficiency.
Normally moderate expression of TFF3 was highly
increased in stomach.
Introduction
TFF peptides (trefoil factor family: TFF1, TFF2 and
TFF3) belong to an evolutionary old [1] family of small
(6-12 kDa) protease resistant peptides that share a
conserved distinct motif of six cysteine residues forming
characteristic disulfide bonds defining a so-called TFF
domain [2]. TFF peptides are predominantly expressed
by mucin-producing epithelial cells of the gastrointestinal
(GI) tract but also in some other tissues [3]. In the GI
tract TFF1 is expressed by gastric surface mucous cells
[4] while TFF2 is present in antral and pyloric glands of
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Table 1. Primers used
the stomach and within the Brunner's glands of the
duodenum [5]. TFF3 is expressed by goblet cells of the
intestine and colon [6] and weakly in stomach [7, 8].
The GI epithelium is daily confronted with frequent insults
and the maintenance of epithelial integrity is of crucial
importance. Upon injury the epithelial cells spread and
migrate across the basement membrane (known as
restitution) within minutes to re-establish surface cell
continuity. Regeneration occurs later on and involves
proliferation and differentiation of epithelial cells and
restoration of specialized elements. The TFF peptides are
rapidly and strongly up-regulated after epithelial damage
[9], in gastric ulceration [10] and inflammatory bowel
disease [11, 12]. TFFs facilitate restitution [13] and re-
epithelialization by stimulating cell migration [14, 15],
inhibiting apoptosis [16, 17] and reducing antigen access
to the healing epithelium by augmenting the barrier function
of mucus through an increase of its viscosity [18]. In
addition, they participate in the mucosal immune response
by stimulating immunocyte migration [19] and are
Cell Physiol Biochem 2005;16:31-42
D
ow
nl
oa
de
d 
by
: 
14
9.
12
6.
78
.6
5 
- 1
1/
17
/2
01
5 
10
:5
1:
01
 A
M
33
Fig. 1.Targeting strategy of the
TFF2 gene and Genotyping of
progeny from crosses. (A) The
wild type TFF2 locus is shown
in the upper line. To construct
the targeting vector a proximal
PstI/XhoI fragment and a distal
2.4-kb fragment, generated by
PCR using the PK1 and PK2
primers, were inserted into
appropriate restriction sites of
the pL2-neo vector. The exon 2
and a part of exon 1 were deleted
in this process (targeting vector
pL2∆m2, middle). The targeted
allele generated by homologous
recombination is shown at the
bottom. A, AatII; B, BamHI; C,
ClaI; H, HindIII; K, KpnI; P, PstI;
X, XbaI and XhoI. Horizontal
arrows indicate primer (PK1 and
PK2) orientations. (B) Southern
blot analysis of the TFF2 locus
from a BamHI digest for the null
mutation. Genomic DNA was
extracted from tail biopsies of
wild-type (wt), heterozygous
(het) and TFF2-/- mice. The
fragment sizes are indicated. The
6-kb represents the targeted
allele. (C) Northern Blot analysis
of stomach RNA using TFF1
(top) and TFF2 (bottom) exon-
probes. TFF2-/- mice show no
expression of TFF2 mRNA
regulated by both pro-inflammatory [20, 21] and anti-
inflammatory cytokine expression [22, 23] acting through
diverse transcription factors [21, 24-26]. Treatment with
exogenous TFF peptides demonstrated both protective
and healing functions in stomach and colon [27-29].
Most valuable data about TFF peptide functions were
obtained from separate TFF knock-out animal models.
TFF1-/- mice developed antropyloric adenomas and
occasionally carcinomas, suggesting a tumour suppressor
function of TFF1 [30]. TFF3 knock-out animals showed
increased sensitivity to dextran sulphate sodium-provoked
intestinal damage [31] with increased intestinal apoptosis
[17]. TFF2 deficient mice appeared more susceptible to
ulceration upon indomethacine treatment [32]. These
pleiotropic effects of TFFs are compatible with their high-
resolution structures suggesting that each TFF peptide
has a specific target or group of target molecules [33].
To study in detail the molecular events behind TFF2
deficiency, we investigated alterations of gene expression
in response to lack of TFF2, by comparing 12,000 genes
using mouse expression microarrays in tissues expressing
TFF2 (pyloric antrum of the stomach, with Brunner's
glands of the duodenum). Genes with significantly altered
expression were further tested by quantitative real time
PCR (qPCR) or by Northern blots. Protein expression
was assessed immunohistochemically.
(bottom) compared with wild-type (wt) or heterozygous (het) animals. The identical blot probed with TFF1 cDNA displays
expression of TFF1 mRNA (top) in all animals. Lane marked with an asterisk (*) is unloaded. (D) TFF2-/-mice express no TFF2
protein as shown by Western Blot in (A)-unboiled and (B) boiled tissue homogenates of stomach.
Cell Physiol Biochem 2005;16:31-42Trefoil factor 2 and immune system
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Materials and Methods
Generation of TFF2 -/- mice
All procedures involving living animals were approved
by the local ethical committee (CRUK). Two fragments were
subcloned into the AatII/XbaI and ClaI/BamHI sites of the pL2-
neo vector (kindly provided by C. Dickson, CRUK). First, a 2.4-
kb fragment containing exon 3 and 4 of TFF2 gene generated
by PCR using PK1 (5-GGATCGATCCCCATCCCATACCC-3)
and PK2 (5-CGGGATCCTATAGGGTCTGAGGTC-3) primers
was subcloned into the ClaI/BamHI site of the targeting vector.
Secondly, the PstI-XhoI fragment (3-kb), derived from 129/Sv
genomic BAC-DNA harbouring genomic mouse DNA (Research
Genetics, USA), containing the first four codons of exon 1, was
first subcloned by shotgun cloning into the PstI-XhoI sites
pBK-CMV (Stratagene, USA) vector, and after a AatII/XbaI
restriction finally into the fitting sites of pL2-neo (Figure 1A
middle). In the applied targeting vector (pL2- m2; Figure 1A
middle) exon 2, which encodes one of the two functional TFF
domains, and exon 1 were deleted. The deletion in exon 1 did
not include the first 13 nucleotides up to the XhoI site. The
targeting vector was linearized with AatII and electroporated
into AB2.2 embryonic stem (ES) cells (Stratagen). After
electroporation and positive selection (G418), ES cell clones
were screened for incorporation of the targeting construct into
the correct genomic locus. DNA was isolated from 552 ES cell
clones and analyzed by both PCR (data not shown) and
Southern blot (see below). One positive clone was identified.
After microinjection into blastocysts from C57BL/6 donors,
high percentage chimaeric animals were obtained which were
mated to C57BL/6 mice, and germ line transmission of the
disrupted TFF2 allele was confirmed by genomic Southern blot
analysis of tail DNA from the progeny. Disruption by
homologous recombination was confirmed by Southern blot
analysis by using the diagnostic BamHI site. For blots, 15 µg
of BamHI digested ES cell or tail genomic DNA was subjected
to agarose (0.7%) gel electrophoresis and transferred to nylon
membranes. A diagnostic probe was labelled by random priming
using [ 32P] dCTP and hybridized to the blots. A 928-bp fragment
(Figure 1A bottom; horizontal bar) of the TFF2 gene was used
as a probe. The wild-type allele generates a 5-kb BamHI fragment
and the heterozygous mutant contains an additional 6-kb
BamHI fragment, representing the targeted allele (Figure 1B).
Complete absence of TFF2 was confirmed by Northern (Figure
1C) and Western blot analyses (Figure 1D).
Northern and western blot analysis
Total RNA was isolated from frozen tissues of the
stomach, particularly of pyloric antrum and Brunner's glands,
from 3 month old mice (RNeasy; Qiagen) The quantity of RNA
was determined spectrophotometrically (Nanodrop). TFF1,
TFF2, and cryptdin cDNA were generated using 129/Sv mouse
genomic DNA template (Table 1). cDNA probes were labelled
by random priming using [ 32P] dCTP. Total RNA (15 µg per
lane) was separated by electrophoresis and transferred to a
nylon membrane and hybridized to specific probes. The
membranes were hybridized overnight at 42 C and washed
before exposing and analyzing in the Phosphor-Imager
(BioRad). To confirm absence of TFF2 protein mouse stomachs
were homogenized in lysis buffer containing 300 mM mannitol,
12 mM HEPES/Tris (pH 7.4), 1 mM PMSF, 0.1 mM benzamidine,
and 0.1µg/ml of antipain. Homogenates were cleared by
centrifugation, resuspended in loading buffer, denaturated by
boiling and separated by SDS/PAGE before transferring to
PVDF membrane. The membranes were blocked (5% non fat
milk in PBS) and incubated over night with polyclonal anti-
mouse TFF2 antibody (produced using peptide EVPWCFFP-
QSVEDCHY for immunization). Signals were detected using
the enhanced chemiluminescence method (Amersham).
Microarray analysis
Total RNA from pyloric antrum with the Brunner's glands
(TFF2 expressing tissues) was isolated (RNeasy kit, Qiagen)
from 3 wild-type (wt) and 3 TFF2-/- mice. RNA was processed
and independently hybridized on a mouse expression array
(MGU74A) containing 12,000 genes (Affymetrix). Scanned
images were processed using Microarray Suite 5.0. The overall
fluorescence intensity across each chip was scaled to target
intensity 150 and pair-wise comparison of mRNA levels was
performed with the wild type samples as a baseline. We
additionally analyzed our microarray data using Significance
Analysis of Microarrays (SAM) [34] with an acceptable false
discovery rate (rough equivalent to P-value) of 0.004%.
Significant alterations were compared with results of Affymetrix
software and only genes displaying signals > 100 in either wt
or TFF2 -/- and changed by factor > 1.6 were accepted.
Quantitative real time PCR
To confirm data of microarray analysis we tested
expression of a number of selected genes using SYBR Green-
based qPCR in 12 wild type and 12 TFF2 deficient animals.
Total RNA was isolated from tissue portions containing (1)
pyloric antrum of stomach with Brunner's glands (pyloric
antrum/Brunner's glands) (as used for Microarray analysis);
Fig. 2. Data set of signal log ratios of different com-
parisons between wild-type and TFF2-/- mice. The
presented genes have a signal intensity >100 and are
significantly changed according to one class analysis
of the Significance Analysis of Microarrays (SAM)
program, with a false discovery rate of 0.004%. Changes
in expression ≥1.6 were considered. The expression pat-
tern of the genes is represented in the horizontal strips
where the tones of red and green represent respectively
the degrees of up- and down-regulation. More intense
colour indicates a higher degree of change: red for up-
and green for down-regulation. The difference in
expression of some genes (see K3xWT1; lane 7) is due
to individual variability.
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(2) mid-portion of duodenum and (3) distal small intestine
(jejunum/ileum). RNA was DNase treated prior to cDNA
synthesis using the iScript TM cDNA synthesis kit (BioRad).
Primer pairs were designed to give only one band (confirmed
by gel electrophoresis and melting curve analysis) and
conditions of reactions were optimized so that efficiency of
PCR reaction was 95-100% (Table 1). Relative quantification
values were obtained from the threshold cycle number of 12
different animals measured in triplicate and normalized with 2
most stable out of 3 tested control genes using the geNorm
program [35]. As control genes we used mouse house keeping
gene (mHKG), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and β-glucuronidase (GUS). Significance was
assessed by Student's t-test.
Immunohistochemistry
Stomach and intestine sections (4 µm) were stained with
haematoxylin-eosin and assessed for pathomorphological
examination. Tissues were stained with antibodies against TFF3
and anti-cryptdin1 prosegment, so called procryptdin (kindly
provided by AJ Ouellette) specifically reacting with all mouse
defensin family precursors [36]. Antigen unmasking for
Fig. 3. Cryptdin level in GI-
tract showed by Northern blot.
Compared to β-actin as control
gene, cryptdins are up-
regulated in the duodenum and
especially in the distal small
intestine of TFF2 deficient mi-
ce.
Fig. 4. Immunoreactivity of
anti-cryptdin1 prosegment in
intestine and TFF3 in stomach
of normal and TFF2-/- mice.
Immunoreactivity of the
cryptdin prosegment localized
in intestinal Paneth cells
(arrows) is more pronounced in
TFF2 deficient mice (B) than in
wild type animals (A). TFF3 in
wt animals is not (or very
slightly) expressed in the
pyloric junction (C), but is
highly present in the pyloric
junction of TFF2 deficient mice.
Brunner’s glands in (A) and (D)
are marked by arrow.
Baus-Loncar/Schmid/Lalani/Rosewell/Goodlad/Stamp/Blin/
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Table 2. Relative changes of mRNA
expression between wild type and
TFF2-/- animals obtained by micro-
array analysis (n=3 each) and
quantitative real time PCR (qPCR)
(n=12 each) in different gastrointesti-
nal regions. Data are expressed as
mean fold changes ±SD. Significantly
changed expression compared to wt
mice is marked with (*)(p<0.05), (n.a.
not available). Abbreviations: Pro-
teasome subunit 5 (PSMB5);
Proteosome subunit, beta type 9
(LMP2); Proteasome subunit Lmp7
(PSMB8); Mus musculus transporter
1(TAP1); Bcl2-associated athano-
gene 2 (BAG2); Cellular retinol
binding protein 2 (CRBP2);
Apolipoprotein A-IV (APO AIV);
Cysteine-rich intestinal peptide
(CRIP); Matrix Metalloproteinase7 (MMP7); Tissue inhibitor of metalloproteinase3 (TIMP3); Mucin 3 (MUC3); Trefoil Factors
(TFF); Glyceraldehyd-3-Phosphat Dehydrogenase (mGAPDH); β-Glucuronidase (GUS); Mouse housekeeping protein (mHKG).
immunohistochemistry was performed by microwaving for 10
min (TFF3) or 3 times for 5min (procryptdin) in 10 mM sodium
citrate, pH 6. The slides were incubated overnight at 4°C in a
humid chamber with anti-TFF3 rabbit serum or with sheep anti-
procryptdin serum. Specific antibody binding was visualized
by biotin-conjugated sheep anti-rabbit IgG (DAKO) or rabbit
anti-sheep IgG (Vector), followed by a streptavidin-biotin-
horseradish peroxidase complex (DAKO) and diaminobenzidine.
Results
Generation of TFF2 -/- mice
Northern blot and Western blot analysis showed
successful disruption of TFF2 gene and complete absence
of TFF2 protein (Figure 1). Pathological analysis of the
animals did not reveal specific gross or microscopic
abnormalities.
Microarray data and confirmation of relevant
genes
Analysis of mRNA levels in TFF2 expressing tissue
of wt and TFF2 -/- animals showed 128 genes with
significantly changed expression according to Affymetrix
and SAM data analysis. We found 78 genes to be up-
regulated and 50 genes down-regulated by factor >1.6.
Further analysis involved grouping genes according to their
function: a) immune response, b) detoxification, c) cell
signalling and transcription factors, d) digestion and
nutrient transport. Signal log ratios of all 9 comparisons
are visually represented (Figure 2) using Genesis software
[37]. When matching wt/TFF2-/- crosswise fashion,
expression levels for some of the genes were not uni-
form possibly reflecting biological variability. The majority
of the genes concerned are involved in immune response.
Among the most prominently up-regulated genes are
several members of the cryptdin family (cryptdin 2,3,5,6
and defensin related cryptdin peptide); mouse orthologues
of human defensins playing a crucial role in innate
immunity. Genes coding for different Ig chains were also
up-regulated.
Microarray analysis revealed significant change in
several genes involved in MHC class I antigen
presentation such as: different proteosomal subunits
(PSMB5, LMP2 and LMP7), TAP1 (subunit 1 of
transporter associated with antigen processing) and
BAG2 (BLC2-associated athanogene 2), a member of
the BAG protein family regulating chaperone activities.
In addition to the expected complete absence of TFF2
mRNA, members of the less known family of murine
urinary proteins (MUPs) were down-regulated as well.
To substantiate the microarray analysis we analyzed some
of the interesting genes by qPCR in 12 different animals
(Table 2).
We tested expression in tissues of pyloric antrum/
Brunner's glands, duodenum and jejunum/ileum. To get
the most reliable data, qPCR measurements were
Cell Physiol Biochem 2005;16:31-42Trefoil factor 2 and immune system
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normalized against the 2 most stable out of  3 control
genes using the geNorm program. Pyloric antrum/
Brunner's glands were normalized against GAPDH/GUS;
duodenum against GUS/mHKG and jejunum/ileum against
GAPDH/mHKG normalization factors. Possible
differences in sampling the tissues of pyloric antrum/
Brunner's glands was excluded by monitoring the
expression of  Mucin 3 exclusively present in intestine
[38]. QPCR data showed that there was no significant
difference in Mucin 3 expression (excluding variable
presence of intestinal tissues) between wt and TFF2-/-
tissue samples.
Real time qPCR data confirmed changes in mRNA
levels of proteosomal subunits. Constitutive PSMB5
subunit was significantly down-regulated (~2-fold) in all
tissues analyzed. Substituting subunit LMP2 was up-
regulated (~1.5-fold) in pyloric antrum/Brunner's glands
and duodenum and slightly, but significantly, up-regulated
(1.3-fold) in the distal portion of the small intestine. In
contrast, subunit LMP7 was significantly up-regulated
(~1.5-fold) but exclusively in the jejunum/ileum.
TAP1 gene showed significant (~2-fold) up-
regulation only in tissues from pyloric antrum/Brunner's
glands. BAG2 protein that regulates chaperone activities
showed significant down-regulation between ~1.5-fold
(duodenum) and ~1.8-fold in the jejunum/ileum.
Cellular retinol binding protein, type 2 (CRBP2) that
complexes vitamin A [39] was significantly up-regulated
(~1.7-3.3 fold) as was apolipoprotein AIV (APO AIV)
involved in fat metabolism (~ 1.5-3.0 fold).
Cathepsin C or dipeptidyl peptidase I (DPPI), a
lysosomal cysteine protease involved in protein turn over
in cells [40], showed significant up-regulation in the
duodenum and the distal small intestine (~1.5-2.0 fold).
Some of the genes expressed in Paneth cells,
providing host defense against microbes, were
significantly changed in TFF2 -/- animals. Cysteine rich
intestinal protein (CRIP) was up-regulated about 2-fold
in pyloric antrum/Brunner's glands and the duodenum.
Several cryptdins, microbe killing molecules
produced in Paneth cells, showed strong up-regulation
(~4.0-9.0 fold). A Northern blot probe hybridizing with
the most relevant cryptdins corroborated the same up-
regulation of cryptdins in ileum/jejunum of TFF2 -/- animals
(Figure 3). In addition, immunostaining with procryptdin1
antibody indicated an increased amount of defensin
precursors (Figure 4A&B). The bactericidal activity of
some of the cryptdins requires post-translational
proteolytic activation of precursors by matrix
metalloproteinase-7 (MMP-7) [41] which can be
specifically inhibited by tissue inhibitor of
metalloproteinases 3 (TIMP3). However, qPCR showed
no significant change in level of MMP-7 and TIMP3
mRNA between wt and TFF2 -/- animals (Table 1).
TFF3 expression was more than ~40 fold up-
regulated at the junction of the pylorus and duodenum,
and ~2 fold up-regulated in the duodenum. While hardly
present in the pyloric antrum of wt animals, TFF3 was
strongly expressed in the same region of TFF2 -/- mice
(Figure 4C&D). Mucin 3 (MUC3) is prominent in the
intestine as a component of the protective mucus layer
[42, 43]. It showed a ~2 fold up-regulation in the duodenum
and in the end portion of the small intestine (Table 2).
Discussion
Anti-apoptotic and motogenic TFF peptides play an
important role in the maintenance of epithelial integrity,
protection and wound healing [3, 13]. Present data suggest
that TFFs are multifunctional peptides. Many of these
facts have been collected thanks to TFF knock-out animal
models. While TFF1 deficient mice [30] display gross
morphological changes (including gastric tumour
development), TFF3-deficient animals show mild
phenotypes unless chemically challenged [16]. TFF2-
deficient animals, compared to wild type, showed greater
mucosal inflammation in response to DSS treatment or
Helicobacter felis infection, while LPS treatment resulted
in increased circulating levels of proinflammatory
cytokines (T. Wang, personal communication, 2004).
Monitoring altered mRNA levels in gastric mucosa
using microarray technology revealed some interesting
consequences of TFF2 deficiency pointing to its role in
immune defence. An important part of immune surveillance
is the presentation of endogenous and exogenous
antigenic peptides to immune cells. Almost all nucleated
cells express on their surface MHC class I molecules,
glycopeptides presenting different endogenous peptide
antigens produced within the cell to cytotoxic lymphocytes.
These endogenous peptides are degraded via the normal
intra-cellular protein degradation pathway and presented
at the cell surface by MHC class I molecules. Proteins
targeted for proteolysis are mainly ubiquitinated and
degraded by large multifunctional protease complexes
termed proteasomes [44]. The immune system appears
to modify the proteasome by displacing the housekeeping
subunits PSMB5 and PSMB 6 with LMP2 and LMP7
Baus-Loncar/Schmid/Lalani/Rosewell/Goodlad/Stamp/Blin/
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subunits whose expression can be induced by increased
levels of IFN-α [45] or by TNF-α [46]. These
immunoproteasomes facilitate antigen presentation
presumably by altering the cleavage specificities of
proteasomes [45, 47]. Degraded short peptides are moved
from the cytosol into the lumen of endoplasmatic reticulum
(ER) by the TAP transporter composed of TAP1 and
TAP 2 subunits and finally transported through the Golgi
complex to the plasma membrane. Proper functioning of
this system is crucial for combating infections and
neoplastic changes.
TFF2 -/- animals showed significantly changed
expression of important genes involved in MHC class I
molecule presentation. Changes in mRNA levels suggest
possible differences in proteasome composition. A
constitutive PSMB 5 subunit is substituted by LMP2
(pyloric antrum and duodenum) and LMP7 (distal small
intestine) subunits forming immunoproteasomes.
Additionally, the TAP1 subunit, often down-regulated in
several tumours and infections [48] is up-regulated in
pyloric antrum and Brunner's glands. Forming MHC class
I-protein complexes depends on the proper folding of
proteins promoted by chaperones. Microarray analysis
revealed no changes in the expression of calnexin and
tapasin chaperones, both important for MHC class I
presentation. Interestingly, we discovered a significant
reduction (~1.5-1.8 fold) of chaperone cofactor BAG-2
as confirmed by qPCR in all tissues examined. The BAG
family of proteins regulates chaperone activities through
their interactions with Hsc70/Hsp70 molecules that are
involved in diverse cellular processes [49, 50]. It is known
that BAG-family proteins are over-expressed in several
cancers and it has been demonstrated in vitro that they
enhance cell survival and proliferation [50]. Recently
BAG2 was recognized as a member of possible novel
signalling pathway for response to cellular stresses [51].
Remarkably, molecular analysis of antropyloric tumours
of TFF1 deficient mice showed an accumulation of
misfolded proteins in the ER, which connected TFF1
deficiency to the unfolded protein response [52].
TFF2 deficient animals displayed increased CRBPII
and APO AIV mRNA, genes which were found to be
up-regulated in intestine as a part of intestinal adaptation
[53, 54]. CRBP II, abundantly expressed in intestinal
epithelial cells, plays a pivotal role in absorption and
metabolism of retinol and beta-carotene which are
involved in maintaining immunity and epithelial turn over
[55]. Animal models showed that vitamin A deficiency
inhibits intestinal adaptation following partial small intestine
resection by reducing crypt cell proliferation, enhancing
early crypt apoptosis and reducing enterocyte migration
[56]. Recently it was recognized that retinoids act as
multistep modulators of the MHC class I presentation
pathway up-regulating proteosomal LMP2 and LMP7
subunits, increasing the half-life of MHC class I
complexes and enhancing the sensitivity of neuroblastoma
cells to lysis by cytotoxic lymphocytes [57]. Up-regulation
of CRBPII in intestine of TFF2 deficient animals probably
reflects an increased need for retinoids that could influence
expression of genes involved in MHC class I antigen
presentation like LMP2, LMP7 and TAP1.
First steps in the defence against invading
microorganisms belong to innate immunity that involves
products of Paneth cells located deep in the intestinal
crypts. Their major products secreted into the lumen of
intestinal crypts are the α-defensins, in the mouse called
cryptdins. Defensins are vital contributors to innate host
antimicrobial defense (direct microbicidal effect) and
recent evidence points to their role as enhancers of ad-
aptive immunity [58]. Some of the cryptdins (cryptdin
2&3) show paracrine actions [59]. They are able to form
pores in epithelial cells and stimulate secretion of some
interleukins [60]. It seems that they are able to coordinate
an inflammatory response with the antimicrobial
secretions of Paneth cells. TFF2- deficient animals show
highly up-regulated levels of cryptdin pre-protein,
especially in the distal small intestine. The bactericidal
activity of some of the mouse cryptdins is dependent on
processing of cryptdin precursors by matrix
metalloproteinase-7 (MMP-7) [36, 41]. MMP-7 and
some other matrix metalloproteinases can be irreversibly
inactivated by tissue inhibitor of metalloproteinases-3
(TIMP3). We did not observe any significant change in
expression of MMP-7 and TIMP 3 by qPCR, although
microarray analysis showed an almost ~2 fold down-
regulation for TIMP3. This points to a more complex
regulation of cryptdin activity than one based solely on
changes of gene expression.
Cysteine-rich intestinal peptide (CRIP), another
highly expressed product of Paneth cells, was also up-
regulated in the duodenum and distal small intestine of
TFF2 deficient mice. CRIP plays a significant role in the
regulation of cytokine balance and the immune response.
Transgenic animals over-expressing CRIP (~3-7 fold)
have changed numbers of different white cell types [61]
and altered cytokine patterns and immune responses [62].
Dipeptidyl peptidase I (DPPI or Cathepsin C), important
for MHC class II antigen presentation [63], was up-
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